J Biol Chem, Vol. 274, Issue 34, 24038-24046, August 20, 1999
Functional Expression of Human PP2Ac in Yeast Permits the
Identification of Novel C-terminal and Dominant-negative Mutant
Forms*
David R. H.
Evans,
Timothy
Myles,
Jan
Hofsteenge, and
Brian A.
Hemmings
From the Friedrich Miescher Institute, Maulbeerstrasse 66, CH-4058 Basel, Switzerland
 |
ABSTRACT |
The protein phosphatase 2A (PP2A) holoenzyme is
structurally conserved among eukaryotes. This reflects a conservation
of function in vivo because the human catalytic subunit
(PP2Ac) functionally replaced the endogenous PP2Ac of
Saccharomyces cerevisiae and bound the yeast regulatory
PR65/A subunit (Tpd3p) forming a dimer. Yeast was employed as a novel
system for mutagenesis and functional analysis of human PP2Ac,
revealing that the invariant C-terminal leucine residue, a site of
regulatory methylation, is apparently dispensable for protein function.
However, truncated forms of human PP2Ac lacking larger portions of the
C terminus exerted a dominant interfering effect, as did several mutant
forms containing a substitution mutation. Computer modeling of PP2Ac
structure revealed that interfering amino acid substitutions clustered
to the active site, and consistently, the PP2Ac-L199P mutant protein was catalytically impaired despite binding Tpd3p. Thus, interfering forms of PP2Ac titrate regulatory subunits and/or substrates into non-productive complexes and will serve as useful tools for studying PP2A function in mammalian cells. The transgenic approach employed here, involving a simple screen for interfering mutants, may be applicable generally to the analysis of structure-function
relationships within protein phosphatases and other conserved proteins
and demonstrates further the utility of yeast for analyzing gene function.
 |
INTRODUCTION |
Protein phosphatase 2A
(PP2A)1 is a ubiquitous
eukaryotic enzyme that is highly conserved between species (1, 2) and a
member of the PPP family of protein Ser/Thr phosphatases that includes
PP1 and calcineurin (3). PP2A is implicated in diverse cellular
processes (4) and coordinates signal transduction through direct,
regulatory interaction with protein kinases (5, 6). PP2A exists as a
holoenzyme in which the catalytic subunit (PP2Ac) binds a regulatory
PR65/A subunit to form a core dimer, which associates with a large
number of variable B subunits encoded by at least three gene families
(7-11). Regulatory subunits of PP2A influence its substrate
specificity and intracellular targeting (12-14), and enzyme activity
is modulated further by post-translational modification of the PP2Ac C
terminus (4).
The budding yeast Saccharomyces cerevisiae possesses two
proteins Pph21p and Pph22p similar to mammalian PP2Ac (15). The homologous PPH21 and PPH22 genes encoding yeast
PP2Ac are functionally redundant because either can be deleted without
effect. However, doubly deleting PPH21 and PPH22
causes severe growth inhibition and is lethal in the absence of
PPH3, encoding a distantly related protein phosphatase that
provides overlapping function (16). Conservation of PP2A extends to the
holoenzyme because the S. cerevisiae Tpd3p (17), Cdc55p
(18), and Rts1p (19) are similar to the regulatory PR65/A, PR55/B, and
PR61/B' subunits, respectively, of mammalian PP2A, and Tpd3p and Cdc55p
bind Pph21p/Pph22p in vivo (20). This suggests that PP2A
regulation is conserved between species, and consistent with this, a
novel methyltransferase that targets the PP2Ac C-terminal leucine
residue and modulates PP2A activity (21) is present in both higher
eukaryotes and yeast (22, 23).
The role of PP2A has been studied biochemically, through the use of
inhibitors and viral tumor antigens that target the enzyme specifically, and genetically, via inactivating subunit mutations. Moreover, the crystal structure of the PR65/A subunit of PP2A was
recently solved (24). Together these studies have implicated PP2A in
processes including cell cycle regulation, cellular morphogenesis, protein synthesis, and viral replication (4). Although the biochemical
and functional properties of PP2A differ from those of protein
phosphatase type 1 (PP1), the catalytic subunits of these enzymes share
~46% amino acid sequence identity. The crystal structure of
PP1
1 has been solved (25, 26) and provides a framework
for predicting the role of specific PP2Ac residues and interpreting the
effect of changes generated by mutagenesis. In this study, we have
functionally expressed human PP2Ac in S. cerevisiae and used
this as a convenient system to generate novel mutations in human PP2Ac
and analyze their effect on PP2A function in vivo. We have
identified a number of novel, interfering mutant forms of PP2Ac and
rationalized their effects using a model of PP2Ac structure based on
that of PP1
1.
 |
EXPERIMENTAL PROCEDURES |
Strains, Media, Plasmids, and Sequence Analysis--
Yeast
strains are described in Table I. Rich
(yeast peptone medium, YPD), minimal (synthetic dextrose, SD), and
5-FOA media were described (27). Plasmids pBluescript II (pBS;
Stratagene), pYES2 (Invitrogen), pYPGE2 (28), pASZ11 (29), pRS314,
pRS316, YEp351, YEp352, YCpDE1, and YCpAS6 (30) were described. DNA constructs were sequenced with dRhodamine dye terminators using Perkin-Elmer GeneAmp PCR system 2400, 9700 thermocycler and analyzed using an Applied Biosystems PRISM 377 sequencer. Pairwise alignment of
human PP2Ac
and yeast Pph22p was performed using ALIGN (Baylor College of Medicine).
Manipulation and Analysis of Human PP2Ac
cDNA--
Two
forms of HsPP2Ac tagged with the HA epitope were used. A single HA tag
was inserted downstream of the PP2Ac
initiation codon, by
amplifying the human cDNA (31) in the PCR using an appropriate
forward primer. A SalI/KpnI
HA-PP2Ac
clone, or a frameshifted allele,
HA-PP2Ac
-FS lacking the second nucleotide of the ninth
codon, was introduced between the PGK1
promoter/CYC1 terminator of vector pYPGE2 generating
plasmids YEpDE-PGK-C
and YEpDE-PGK-FS. A similar
NcoI/BamHI fragment was introduced into vector
pACTII (P. Legrain, Pasteur Institute) fusing the
HA-PP2Ac
ORF to the Gal4 activation domain. A
second sequence encoding an extended HA-PP2Ac
ORF was
used for HsPP2Ac immunoprecipitation experiments because it encodes
native HsPP2Ac with an epitope accessible to the 12CA5 antibody (32).
PP2Ac
containing this tag was introduced into vectors
pYPGE2 (YEpDE-PGK-CHA) and pYES2 (YEpDE2-C
HA), and similarly tagged
PP2Ac-2512 and PP2Ac-118 alleles were introduced
into pYES2 (YEpDE-GAL-2512HA and YEpDE-GAL-118HA). Mutations were
generated in HA-PP2Ac
by PCR amplification using QuickChange (Stratagene). Truncations of the HA-PP2Ac
ORF
were generated in vitro by PCR using a reverse primer that
introduced a stop at codon 309 (PP2Ac-
309), 301 (PP2Ac-
300), or 67 (PP2Ac-
67) (codon
numbering for untagged PP2Ac
). PP2Ac
mutant
alleles were inserted between the HindIII/BamHI
sites of pYES2 and downstream of SalI in pYPGE2. Plasmid DNA
was prepared from strain DEY1-C
using a Kristal extraction kit
(Cambridge Molecular Technologies); six plasmids, recovered from
independent ampr Escherichia coli colonies, were
tested for a restriction pattern (SalI/KpnI or
XbaI) identical to that of YEpDE-PGK-C
. The nucleotide sequence of one plasmid was analyzed, and it encoded
YEpDE-PGK-C
.
Preparation of Yeast Cell Extracts and Western Blot
Analysis--
Cell extracts were prepared as described (33). Protein
transfer and Western blotting were as described (9). Antibodies were
diluted in TNPT (1.0% Nonidet P-40, 0.3% Triton X-100 in Tris-buffered saline (TBS, 150 mM NaCl, 50 mM
Tris-HCl, pH 7.5)) containing 7.5% powdered milk. Membranes were
washed with TNPT. Detection was by goat anti-mouse IgG-HRP and ECL
(Amersham Pharmacia Biotech).
Construction of the pph22
52 Allele and myc-TPD3
Alleles--
The PPH22 gene was PCR-amplified using a
forward primer appropriate to generate pph22
52 encoding
an initiation codon followed by codons 53-377 of PPH22 and
a stop codon TAA. A pph22
52 1.0-kb SalI/KpnI fragment was fused to the
PGK1 promoter in pYPGE2. A 3.4-kb genomic fragment
encompassing the yeast TPD3 gene (17) was inserted into
YEp351 (YEpDE11) and was template for a PCR generating a
TPD3 ORF, flanked by its native promoter/terminator, with a
double c-myc tag downstream of the initiator codon
(myc-TPD3). A 3169-base pair myc-TPD3
SacI/SalI fragment was inserted into vectors pRS314,
YEp351, and YEp352 (YCpDE3-2m, YEpDE3-2m, and YEpDE4-2m, respectively).
The myc-TPD3 allele is functional because YCpDE3-2m rescued
the ts growth defect of haploid tpd3
1::URA3 mutant cells (not shown).
Immunoprecipitations and Protein Phosphatase Activity
Measurements--
To precipitate HA-tagged proteins, PAS CL-4B
(Amersham Pharmacia Biotech) equilibrated in 1× TBS was incubated at
4 °C with 12CA5 overnight and then washed extensively (six times
with 10 volumes of TBS). Antibody-saturated beads (PAS-12CA5, 35 µl)
were added to ~100 µl of yeast extract, incubated at 4 °C for
2 h, and washed extensively. Phosphatase assays (50 µl) were
performed on immune complexes according to Promega (kit V2460)
measuring phosphate release over 10 min from a chemically synthesized
phosphopeptide (RRA(pT)VA, where pT indicates phosphothreonine) with
MnCl2 present at 1 mM. Assays were performed in
duplicate on immune complexes prepared independently, and activity is
expressed as units (1 unit = 1 µmol of phosphate hydrolyzed per
min). For co-immunoprecipitations, cell extracts were prepared in
Buffer A (100 mM Tris-HCl pH 7.5, 200 mM NaCl,
1.0 mM EDTA, pH 8.0, 0.5 mM dithiothreitol,
0.1% Nonidet P-40) with protease inhibitors. PAS-12CA5 (35 µl) was added to 1.0 mg of extract, incubated at 4 °C for 2-5 h, washed extensively with Buffer A, and boiled in 50 µl of Laemmli Buffer.
Generation of PP2Ac
Dominant-negative Alleles--
A 970-base
pair HindIII/BamHI HA-PP2Ac
fragment was inserted into the GAL1/CYC1 promoter/terminator
cassette of pYES2, and this plasmid, YEpDE-C
HA, was cleaved with
AflII/BstEII generating a gap within the
PP2Ac
ORF. In parallel, the intact insert in YEpDEC
HA
was amplified under mutagenic conditions for the PCR (0.2 ng/µl
template DNA, 1× reaction buffer (Perkin-Elmer), 0.5 pmol/µl primer
T7, 0.5 pmol/µl primer 20622 (5'-AGAGGATCCTTACAGGAAGTAGTCTGGGGTACGACGAGTAAC), 0.5 mM each dCTP and dTTP, 0.1 mM each dATP and
dGTP, 3 mM MgCl2, 0.1 or 0.2 mM
MnCl2, 5 units of Taq polymerase, 33 cycles of
94 °C for 1.5 min, 55 °C for 2.0 min, 72 °C for 3.0 min).
PP2Ac
mutant alleles were recovered by co-transforming
(34) cells (strain DEY1-C
) with gapped plasmid DNA (0.5 µg) and
mutagenic PCR product (200 ng). Ura+ transformants were
selected on SD lacking uracil and then replica-plated to synthetic
dextrose (SD) and synthetic galactose (SG) medium to identify plasmids
containing dominant-negative alleles expressed from the GAL1
promoter. Plasmids recovered from cells capable of growth on glucose
but not galactose were checked for gap repair by restriction analysis
and reintroduced into DEY1-C
to confirm growth inhibition on
galactose. To test competition between PP2Ac
wild type
and mutant alleles, the 2.3-kb SnaBI/EcoRI
fragment from YEpDE-C
HA, containing HA-PP2AC
fused to
the GAL1 promoter, was inserted between the
SmaI/EcoRI sites of vector pASZ11[CEN.ARS ADE2] and named YCpDE11-GAL-C
. The HA-PP2Ac
-FS
allele was similarly inserted into pASZ11 (YCpDE11-GAL-FS) as a
negative control for PP2Ac
function. To express
PP2Ac-2512 from the GAL1 promoter in pASZ11 the
0.75-kb NcoI/SacI fragment of YCpDE11-GAL-C
was replaced by the equivalent DNA from YEpDE-GAL-2512
(PP2Ac-2512 in pYES2) and tested (plasmid YCpDE11-GAL-2512)
for inducible growth inhibition in DEY1-C
as above.
Galactose-induced Expression of PP2Ac
in Cells Grown in Liquid
Medium--
PP2Ac
wild type and mutant alleles were expressed from
the GAL1 promoter of pYES2 in yeast strain INVSC1. Cells
were grown to a density of 5.0 × 106 per ml at
30 °C in selective (synthetic raffinose, SR) medium containing
raffinose (2.0%), glycerol (3.0%), and casamino acids (0.2%)
followed by the addition of an equal volume of SG medium containing
galactose at 4.0%.
Modeling of PP2Ac Structure--
A homology-based model was
obtained using the coordinates of PP1
1 (a gift from Dr.
David Barford, University of Oxford). Residues 1-309 of human PP2Ac
and 8-316 of human PP1
1 were aligned using "GAP"
(GCG Wisconsin Package, Madison, WI). The optimal alignment (46%
identity with four 1-amino acid gaps) was used by "MODELER" (Ref.
35; BIOSYM/Molecular Simulations, San Diego, CA) to build and refine
five PP2Ac models. PP1
1 appears unstructured between
residues 299 and 316 (25), and no models were obtained for PP2Ac in
this region (the C terminus of the models is Pro-291). The best model,
selected on the basis of the lowest violations of the probability
density functions, was evaluated using "Profiles-3D" (Ref. 36;
BIOSYM/Molecular Simulations, San Diego, CA). Its overall
self-compatibility score, 139.2, was close to that expected for a
polypeptide chain of this length, 140.6, indicating reliability of the model.
 |
RESULTS |
Functional Replacement of Yeast PP2Ac by Human PP2Ac--
The
primary structure of PP2Ac is highly conserved from yeast to humans
(2); excluding an N-terminal extension (~50 residues) to the S. cerevisiae protein, the yeast and human PP2Ac polypeptides display
71% amino acid sequence identity. To investigate whether the
conservation of PP2Ac structure reflects a conservation of function, we
tested the ability of human PP2Ac (HsPP2Ac) to functionally replace the
corresponding protein from S. cerevisiae (ScPP2Ac). We used
haploid yeast cells (strain DEY1) triply deleted for the chromosomal
PPH21, PPH22, and PPH3 genes and
supported by a plasmid-borne PPH22 gene encoding ScPP2Ac
(30). A second plasmid, carrying the human PP2Ac
clone
fused to the yeast PGK promoter and the hemagglutinin
epitope, was introduced, and heterologous expression of HA-tagged
HsPP2Ac was analyzed by immunoblot analysis (see Fig.
1A). Two forms of HsPP2Ac were detected,
suggesting that the human protein undergoes post-translational
modification in yeast, and both forms migrated at approximately 36 kDa,
faster than the endogenous ScPP2Ac at 43 kDa (not shown). HsPP2Ac was analyzed for function in yeast using a plasmid shuffling assay, testing
for the ability of cells to grow in the absence of ScPP2Ac (Fig. 1B);
this assay tests for the ability of yeast cells to grow on medium
containing 5-FOA (37) which negatively selects against the essential
URA3 PPH22 plasmid encoding ScPP2Ac in strain DEY1. Cells
containing PP2Ac
lost PPH22 at high frequency
and grew on 5-FOA medium, whereas cells containing a non-functional PP2Ac
clone with a 5'-frameshift (PP2Ac
-FS)
or the empty vector failed to grow without PPH22. An
incoming TRP1 PPH22 plasmid also substituted for the
resident URA3 PPH22 plasmid as expected. This indicates that
HsPP2Ac is functional in yeast and that it supports cell growth in the
absence of ScPP2Ac. Consistent with this, cells cured of
PPH22 by plasmid shuffling contained plasmid DNA carrying the PP2Ac
clone (see "Experimental Procedures") and
expressed the 36-kDa HsPP2Ac (Fig. 1A). Moreover, in an
alternative test of function (Fig. 1C), PP2Ac
rescued the ts growth defect of pph22-172 mutant yeast cells
that undergo loss of endogenous ScPP2Ac function at 37 °C because of
a conditional-lethal point mutation in PPH22 (30). In
addition, a truncated allele of PPH22 lacking the first 52 codons (pph22
52) functionally replaced full-length PPH22 in strain DEY1 (Fig. 1D) even at 37 °C
(not shown) indicating that the N-terminal extension to ScPP2Ac is
dispensable for cell viability, consistent with the ability of HsPP2Ac
to replace the endogenous yeast enzyme.

View larger version (36K):
[in this window]
[in a new window]
|
Fig. 1.
Functional expression of human PP2Ac in
yeast. A, Western blot analysis of HA-tagged HsPP2Ac.
Yeast cell extracts (10 µg) were resolved by SDS-PAGE and probed with
12CA5 monoclonal antibody. Lane 1, strain DEY1-P2
(expressing untagged ScPP2Ac); lane 2, strain DEY1-C
(expressing HA-tagged HsPP2Ac). Molecular mass marker shown on the
right. B, functional replacement of ScPP2Ac
(Pph22p) by HsPP2Ac via plasmid shuffling. TRP1 plasmids
carrying human PP2Ac (YEpDE-PGK-C ), the frameshifted
allele PP2Ac -FS (YEpDE-PGK-C FS), no insert (vector
pYPGE2), or yeast PPH22 (YCpDE1) were introduced into strain
DEY1, and cells were grown to saturation (5 × 107
cells/ml) in liquid SD with uracil. Cell suspensions (5 µl) were
diluted (1:1, 1:10, or 1:100), spotted onto agar medium containing
(5-FOA) or lacking (SD + uracil) 5-fluoroorotic
acid, and incubated at 30 °C for 3 days. C, suppression
of the pph22-172 ts mutant growth defect by
PP2Ac . Cells of strain DEY107 containing
PP2Ac (YEpDE-PGK-C ) vector (pYPGE2) or
PPH22 (YCpDE1) were grown to saturation in selective SD, and
cells (5 µl, diluted 1:1 or 1:10) were spotted onto YPD agar and
incubated at 37 °C or 24 °C for 36 h. D,
functional replacement of wild type PPH22 by the
pph22 52 allele. Cells (strain DEY1) containing either
pph22 52 (YEpDE-PGK- 52) vector (pYPGE2) or
PP2Ac (YEpDE-PGK-C ) were grown to saturation in SD
with uracil and spotted onto 5-FOA as described in B. pph22 52 cells (strain DEY1- 52) obtained on 5-FOA displayed
wild type growth at 37 °C (not shown).
|
|
HsPP2Ac Binds the Yeast PR65/A Subunit, Tpd3p--
Because PP2Ac
heterodimerizes with a regulatory PR65/A subunit (1), we tested whether
HsPP2Ac binds the endogenous yeast PR65/A subunit Tpd3p in
vivo. We tagged Tpd3p with the Myc epitope (Myc-Tpd3p) and asked
whether it co-precipitates with HA-tagged HsPP2Ac from a yeast extract
(Fig. 2A). When proteins were
precipitated using the 12CA5 antibody, Myc-Tpd3p but not untagged Tpd3p
was detected in an immune complex prepared from cells expressing
HA-HsPP2Ac, whereas Myc-Tpd3 was absent from a similar complex prepared
from cells expressing ScPP2Ac lacking the HA epitope. This indicates HsPP2Ac binds the yeast PR65/A subunit and that, consistently, HsPP2Ac
interacted with Tpd3p in the yeast two-hybrid system (Fig. 2B). This supports the conclusion that HsPP2Ac is functional
in yeast. Moreover, HsPP2Ac prepared from yeast was catalytically active (see below).

View larger version (35K):
[in this window]
[in a new window]
|
Fig. 2.
HsPP2Ac binds the endogenous yeast regulatory
PR65/A subunit, Tpd3p. A, the Myc-tagged Tpd3p
co-precipitates with HA-tagged HsPP2Ac. Yeast extracts were prepared
from cells expressing HA-HsPP2Ac and Myc-Tpd3p (strain DEY1-c42m),
HA-HsPP2Ac and untagged Tpd3p (DEY1-c352), or untagged ScPP2Ac and
Myc-Tpd3p (DEY11-42m) as indicated, and HA-tagged proteins were
precipitated with the 12CA5 monoclonal. Following SDS-PAGE and Western
transfer, cell extracts and immune complexes were probed with 12CA5 to
detect HA-HsPP2Ac (~36 kDa) or with the 9E10 monoclonal to detect
Myc-Tpd3p (~73 kDa). Molecular mass markers are shown on the
right. B, HsPP2Ac interacts with Tpd3p in the
yeast two-hybrid system. TPD3 fused to
GAL4DB in vector pAS1-CYH2 (a gift from Mike
Stark, Dundee University) and PP2Ac fused to
GAL4AD in vector pACTII (see "Experimental
Procedures") were introduced into strain Y166 separately or together
as indicated and tested for activation of the
GAL1::URA3 reporter gene; cell suspensions (5 µl) were diluted (1:1 or 1:10), spotted onto SD lacking uracil, and
incubated at 30 °C for 3 days. A similar pattern of activation of
the Y166 GAL1::lacZ reporter was observed (not
shown).
|
|
Interfering Mutant Forms of HsPP2Ac--
We used yeast cells
functionally expressing HsPP2Ac to identify mutant forms of the human
enzyme that interfere with wild type PP2Ac function. A library of human
PP2Ac
mutant alleles, fused to the yeast GAL1
promoter, was generated by random mutagenesis and screened for those
that inducibly inhibited cell growth on galactose medium. Eleven mutant
alleles were identified (Fig. 3) that
dominantly inhibited the growth of cells expressing wild type
PP2Ac
constitutively from the PGK1 promoter
(strain DEY1-C
). The PP2Ac-2512 allele inhibited growth
even when transferred to an alternative GAL plasmid (see
"Experimental Procedures") demonstrating that its dominant-negative
effect was caused by mutation of PP2Ac
and not vector DNA
(not shown). Five mutant alleles contained nonsense mutations within
the PP2Ac
ORF and encoded C-terminally truncated forms of
HsPP2Ac. Of these, the PP2Ac-182 allele encoded the largest
truncation deleting the C-terminal 145 amino acids. A further
dominant-negative allele, PP2Ac-144-2, encoded a
1 frameshift mutation within codon 307 of PP2Ac
, extending
the ORF by 57 codons. Together this indicates that an intact C terminus is required for wild type HsPP2Ac function, and its modification may
cause an interfering effect. However, the PP2Ac-
67
allele, encoding HsPP2Ac lacking residues 68-309 (Fig. 3), did not
cause a dominant-negative effect (see "Discussion"). Another five
PP2Ac
mutant alleles encoded missense mutations, and in
each case (excepting PP2Ac-2446) a single amino acid
substitution was sufficient for dominant inhibition of cell growth
(Fig. 3). Immunoblot analysis of HA-tagged HsPP2Ac proteins revealed
that wild type PP2Ac
and dominant-negative missense
alleles were expressed from the GAL1 promoter to a similar
level, whereas nonsense alleles were expressed to a lower level (data
not shown). Because GAL-expressed wild type
PP2Ac
did not inhibit cell growth, the interfering effect of PP2Ac
dominant-negative alleles must be caused by an
intrinsic property of their products and not by toxic, high levels of
expression.

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 3.
PP2Ac
mutant alleles causing dominant inhibition of yeast cell
growth. Left, the ORF of wild type PP2Ac
and mutant alleles generated in vivo (see "Experimental
Procedures") or in vitro by subcloning or site-directed
mutagenesis. s, position of substitution mutation
(hatched box) frameshift and 57-codon extension to the
PP2Ac ORF encoded by CYC1 vector sequences
caused by deletion of the nucleotide corresponding to T922
in the untagged PP2Ac ORF. Center, allele
names and identity of encoded mutation(s). Substitutions are according
to residue number in untagged HsPP2Ac. Substitutions encoded downstream
of a premature stop codon are in parentheses.
Right, inducible inhibition of yeast cell growth.
Transformant cells (strain DEY1-C ) expressing a PP2Ac
wild type or mutant allele from the inducible GAL1 promoter
were grown to saturation in selective SD. Approximately 100 cells were
spread onto glucose (non-inducing) and galactose (inducing) agar medium
and incubated at 22 °C for up to 7 days. , no colonies
visible by eye; +/ , microcolonies; +, ++, +++,
colonies of approximately 1.0, 1.5, and 2.0 mm diameter,
respectively.
|
|
PP2Ac
Mutant Alleles Inhibit PPH22 and pph22-12 Cell
Growth--
The screen for PP2Ac
dominant-negative
alleles was performed in yeast cells containing human, and lacking
yeast, PP2Ac. To test for growth inhibition in the presence of ScPP2Ac,
we introduced PP2Ac
mutant alleles into PPH22
pph21
pph3
cells, in which Pph22p provides ScPP2Ac function.
When expressed from the GAL1 promoter, each
PP2Ac
dominant-negative allele tested inhibited cell
growth (Table II) suggesting that its
product interfered with ScPP2Ac function. Moreover, when
PP2Ac
dominant-negative alleles were expressed in
pph22-12 pph21
pph3
cells, containing a mutant Pph22p
functionally impaired by a single amino acid substitution but which
nevertheless display wild type growth at 30 °C (30), the
PP2Ac
mutant alleles inhibited growth at 30 °C, and
this inhibition was more severe than that observed in wild type
(PPH22) cells (Table II). Thus, dominant-negative alleles of
PP2Ac
display an allele-specific interaction with
PPH22 and pph22-12 causing severe growth
inhibition when endogenous ScPP2Ac is functionally impaired. These
results support the notion that PP2Ac function is conserved between
species and that inhibitory mutant forms of HsPP2Ac interfere with
endogenous PP2Ac, whether HsPP2Ac or ScPP2Ac.
View this table:
[in this window]
[in a new window]
|
Table II
Dominant-negative effect of PP2Ac mutant alleles on wild-type
(PPH22) and pph22-12 mutant yeast cell growth
PP2Ac alleles (described in Fig. 3) were expressed from the
inducible GAL1 promoter in vector pYES2. Transformed yeast
cells were grown to saturation in SD liquid medium and spread (~100
cells) onto SD (Glu) and SG (Gal) agar medium and incubated at 30 °C
for the length of time indicated.
|
|
Predicted Effect of Dominant-negative Mutations on PP2Ac
Structure--
To gain insight into the interfering effect of
PP2Ac
dominant-negative mutations, we built a model of
HsPP2Ac structure based on the crystal structure of PP1
1
(25). The overall structure of the PP2Ac model (residues 1-291) is
strikingly similar to that of PP1
1 (Fig.
4) with an architecture of 10
-helices
and 3
-sheets. PP1
1 possesses a shallow
substrate-binding site, with a di-nuclear metal ion center at the
catalytic site. In agreement with the observation that PP2A is a
divalent cation-dependent enzyme (1), the predicted HsPP2Ac
metal ligands Asp-57, His-59, Asp-85, Asn-117, His-167, and His-241
(equivalent to Asp-64, His-66, Asp-92, Asn-124, His-173, and His-248 in
PP1
1) are positioned correctly to bind the two metal
ions. Moreover, HsPP2Ac contains the substrate-binding residues Arg-89,
Asn-117, His-118, Arg-214, and Tyr-265 and the auxiliary residue Asp-88
(which may form a catalytically important salt bridge with His-118)
equivalent to Arg-96, Asn-124, His-125, Arg-221, Tyr-272, and Asp-95 of
PP1c
. The longest truncation of HsP2Ac (Cys-165stop, encoded by
PP2Ac-182) deletes two metal ligands, one substrate-binding
residue and a major portion of the active site, and is likely to be
catalytically inactive. Surprisingly, the secondary structural elements
missing from this truncated protein do not form an independent domain
but comprise a subdomain (
7,
8,
-sheet 3 (
7-
9), and
9) and part of
-sheet 2 (
6,
10,
12,
11) and
-sheet
1 (
13,
14). Even the shortest truncation (Tyr-218stop,
PP2Ac-216) similarly lacks
9 and
9 in the subdomain and part of both
-sheets 1 and 2. Presumably the remainder of the
polypeptide in these and the other HsPP2Ac truncation mutants folds
sufficiently to form a subdomain, comprising
1,
4,
3,
2,
and
4-
6, that binds PP2A-interacting proteins and thereby promotes an interfering effect.

View larger version (125K):
[in this window]
[in a new window]
|
Fig. 4.
Computer model of PP2Ac structure. The
-helices are shown as blue cylinders; -sheets as
green arrows; metal ions as purple
spheres. The position of amino acids substituted in this
study and the location of truncations causing an interfering effect are
shown as red spheres and red arrows,
respectively.
|
|
Five PP2Ac
dominant-negative alleles encoded missense
mutations, and the interfering effect of four of these could be
rationalized as they encode substitutions disturbing the PP2Ac active
site and thus may impair catalytic activity. The Y127N substitution (PP2Ac-153-1 allele) changes a highly conserved tyrosine
residue (equivalent to Tyr-134 of PP1
1) that interacts
with the Ser(P)/Thr(P) substrate and whose side chain is in van der
Waals contact with His-118 and Asp-88. Like in PP1
1,
His-118 is predicted to serve as a general acid in the PP2Ac active
site, protonating the Ser(P)/Thr(P) leaving group and accelerating the
phosphatase reaction, whereas Asp-88 may enhance the acidic character
of His-118. The F150I substitution (PP2Ac-225-1) changes a
conserved residue (Phe-156 in PP1
1) which is distant
from the active site but forms a hydrogen bond with the buried Glu-119
residue; Glu-119 is adjacent to His-118 and is in van der Waals contact
with the metal-binding residue Asp-85. Thus, the F150I substitution may
affect the orientation of the Glu-119 side chain and alter metal
ligation, although interestingly, an alternative aromatic residue
tyrosine (PP2Ac-2446-2 allele) is tolerated at this
position. The conserved Leu-199 residue (Leu-205 in
PP1
1) occurs at the C terminus of helix
8 and its
main chain carbonyl group hydrogen-bonds with the side chains of
Asn-117, His-167, and His-241 which are metal ligands. Disruption of
local structure by L199P (PP2Ac-2512) could affect metal
binding, abolish contact with Cys-196, and alter the orientation of
Trp-200 that has been proposed to contact substrate residues flanking
Ser(P)/Thr(P). Finally, the T258P substitution (PP2Ac-136)
changes a highly conserved, penultimate residue of
12 (Thr-265 in
PP1
1) which forms part of
-sheet 2 (
1,
5,
6,
10,
12, and
11). The polypeptide chain emerging from
10
packs on top of this
-sheet and contains the His-241 metal ligand.
Furthermore, the
-methyl group of Thr-258 packs against its main
chain. Thus, a proline at position 258 could interfere with metal
binding by His-241. The fifth dominant-negative missense mutation
encoding V159E (PP2Ac-153-2) is more difficult to
rationalize in terms of a catalytically impaired PP2Ac. However, Val-159 (Val-165 in PP1
1) is part of the hydrophobic
core located between
-sheets 1 and 2. Introducing a negatively
charged glutamate into it could, although distant from the active site,
have a global effect on active site structure and catalysis.
The PP2Ac C-terminal Leucine Residue Is Dispensable for
Function--
Because truncated forms of HsPP2Ac cause an interfering
effect, we explored the functional role of the highly conserved PP2Ac C
terminus. Deleting the HsPP2Ac C-terminal nine amino acids
(PP2Ac-
300 allele) caused an inhibitory effect that was
less severe than that caused by larger truncations (Fig. 3), whereas
deleting the C-terminal Leu-309 residue alone (PP2Ac-
309)
caused no interfering effect (not shown). The C-terminal leucine
residue is invariant among PP2Ac enzymes, and so we tested whether it
is essential for HsPP2Ac function (Fig.
5). Remarkably, the
PP2Ac-
309 allele functionally replaced the yeast
PPH22 gene encoding ScPP2Ac in strain DEY1, as did
PP2Ac-A309 encoding HsPP2Ac-L309A with alanine at position
309, indicating that Leu-309 is dispensable for HsPP2Ac function
in vivo. In contrast, the PP2Ac-
300 allele
failed to replace PPH22 (Fig. 5) indicating that a largely
intact C terminus is essential. Surprisingly, PP2Ac-
309
supported a rate of yeast cell growth that was higher (doubling time
(td) 3.1 ± 0.49 h in liquid YPD at
30 °C, strain DEY1-
309) than that supported by
PP2Ac-A309 (td 4.6 ± 0.84 h,
strain DEY1-A309) and was similar to that supported by wild type
PP2Ac
(td 2.8 ± 0.28 h,
strain DEY11) (see "Discussion").

View larger version (49K):
[in this window]
[in a new window]
|
Fig. 5.
Functional analysis of PP2Ac
truncation mutants by plasmid shuffling. Cells (strain
DEY1) expressing the PP2Ac- 309, PP2Ac-A309, or
PP2Ac- 300 mutant allele or wild type PP2Ac
from the PGK1 promoter, or the empty pYPGE2 vector, were
incubated on 5-FOA and monitored for growth as described in Fig.
1B.
|
|
PP2Ac-L199P Is Catalytically Impaired but Binds Tpd3p--
To
explore the mechanism by which HsPP2Ac mutant proteins containing a
substitution mutation may interfere with wild type PP2Ac function, we
tested the PP2Ac-L199P protein (PP2Ac-2512 allele) for
catalytic activity in vitro (Fig.
6A). Unlike wild type HsPP2Ac recovered
from yeast, PP2Ac-L199P displayed no detectable okadaic acid-sensitive
phosphatase (PP2A) activity greater than the vector control. This is
consistent with the prediction from molecular modeling that the L199P
substitution inhibits PP2Ac activity by disrupting binding and/or metal
ion-mediated hydrolysis of the substrate and suggests that catalytic
impairment of PP2Ac-L199P may contribute to its interfering effect
in vivo. To test this we analyzed an active site mutant of
HsPP2Ac2 mutated for the
His-118 residue of PP2Ac, which may serve as a general acid in the
active site of PP2Ac protonating the Ser(P)/Thr(P)-leaving group. This
mutant HsPP2Ac possesses a neutral asparagine residue in place of
His-118 which is predicted to dramatically reduce Vmax for the phosphatase reaction (25). Unlike
wild type HsPP2Ac, PP2Ac-H118N displayed no detectable PP2A activity
in vitro (Fig. 6B) supporting the prediction that His-118 is
important for HsPP2Ac catalytic function. Moreover, when the
PP2Ac-118 allele encoding PP2Ac-H118N was expressed from the
yeast GAL1 promoter, it caused an inhibition of cell growth
similar to that caused by PP2Ac
dominant-negative
missense alleles (see Fig. 3). This indicates that catalytic impairment
of HsPP2Ac may cause an interfering effect. Finally, we asked whether
PP2Ac-L199P binds the yeast Tpd3p PR65/A subunit in vivo.
When HA-tagged proteins were precipitated from yeast extracts, the
Myc-tagged, but not untagged, Tpd3p was detected in complexes
containing wild type HA-HsPP2Ac and HA-PP2Ac-L199P but not in complexes
lacking HA-tagged PP2Ac protein (Fig. 6C). Thus, like wild
type HsPP2Ac, PP2Ac-L199P binds the endogenous yeast PR65/A subunit
suggesting that, although catalytically impaired, it folds sufficiently
to bind PP2A-interacting proteins thereby contributing to its
interfering effect on PP2Ac function.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Characterization of the human PP2Ac-L199P
mutant protein. A, PP2Ac-L199P is catalytically
impaired. Phosphatase activity was measured in immune complexes
prepared from yeast containing wild type HA-HsPP2Ac (wt),
HA-PP2Ac-L199P (L199P), or no HA-tagged protein ( ).
B, an active site mutant of HsPP2Ac is catalytically
impaired. PP2A activity was measured in immune complexes containing
HA-HsPP2Ac (wt) or HA-PP2Ac-H118N (H118N) and
corrected for activity present in the absence of HA-tagged protein
( ). HA-tagged forms of HsPP2Ac were inducibly expressed from the
yeast GAL1 promoter of vector pYES2 in cells grown in liquid
galactose medium (see "Experimental Procedures") for 15 h.
Cells containing empty vector served as a negative control ( ).
HA-tagged proteins, precipitated by the 12CA5 monoclonal antibody from
200 µg (A) or 100 µg (B) of yeast cell
extract, were assayed for phosphatase activity in the absence
(open bars) or presence (closed bars) of 10 nM okadaic acid to identify PP2A activity directed against
a phosphopeptide substrate. Numbers represent the mean
values (±S.D.) from four (A) or three (B)
experiments. The inset to A and B
shows a representative Western blot analysis of immune complexes
prepared in parallel with those used for phosphatase assays; HA-tagged
C subunits (C) were present in the relevant complexes at
similar levels and were absent from the (vector) control.
Immunoglobulin heavy and light chains were detected above and below
PP2Ac. C, the Myc-tagged Tpd3p co-precipitates with
HA-PP2Ac-L199P. Extracts were prepared from cells expressing HA-HsPP2Ac
and Myc-Tpd3p (strain DEN2-3m) or untagged Tpd3p (DEN2-11),
HA-PP2Ac-L199P, and Myc-Tpd3p (DEN2512-3m), or untagged Tpd3p
(DEN2512-11), Myc-Tpd3p alone (DEY23m), or untagged Tpd3p alone
(DEY211) as indicated below the blot. HA-tagged proteins
were precipitated with 12CA5, and resolved cell extracts and
immunoprecipitates were probed with 12CA5 or 9E10 monoclonal to detect
HA-tagged PP2Ac (~36 kDa) and Myc-Tpd3p (~73 kDa) respectively.
Molecular mass markers are shown on the right.
|
|
Competition in Vivo between Wild Type and Mutant Forms of
HsPP2Ac--
To probe further the mechanism by which interfering forms
of HsPP2Ac inhibit cell growth, we tested for reversal of growth inhibition by overexpression of wild type HsPP2Ac. PP2Ac
was expressed from the GAL1 promoter in yeast cells
co-expressing a GAL-driven dominant-negative allele, and
PP2A function was assessed by colony formation
(Table III). With one exception
(PP2Ac-316) growth inhibition caused by PP2Ac
missense alleles was alleviated by co-overexpression of wild type
PP2Ac
, as was inhibition caused by
PP2Ac-144-2, encoding the aberrant C-terminal extension to HsPP2Ac. In contrast, a 5'-frameshifted PP2Ac
mutant
clone failed to reverse the growth inhibitory effect of the
dominant-negative alleles, as expected. This suggests that a
competition occurs in vivo between wild type and substituted
mutant forms of HsPP2Ac. Nevertheless, increased expression of
PP2Ac
failed to reverse the growth inhibition caused by
C-terminally truncated forms of PP2Ac suggesting that these inhibit
wild type HsPP2Ac function by a different, non-competitive mechanism.
View this table:
[in this window]
[in a new window]
|
Table III
Competition between human PP2Ac wild type and dominant-negative
alleles expressed in yeast from the GAL1 promoter
Yeast cells (strain DEY1-C ) contained a resident wt
PP2Ac allele expressed at low level from the constitutive
PGK1 promoter (PGK-PP2Ac ) and a resident
dominant-negative allele (GAL-PP2Ac-n) expressed from the
inducible GAL1 promoter of vector pYES2. A wt
(GAL-PP2Ac ) or non-functional, frame-shifted allele
(GAL-PP2Ac -FS) was introduced and expressed from the
GAL1 promoter of vector YCpDE11-GAL-C and YCpDE11-GAL-FS,
respectively. Transformant cells (~100) were spread on SD (Glu) or SG
(Gal) agar medium and incubated at 22 °C for 7 days.
|
|
 |
DISCUSSION |
PP2A Is Functionally Conserved between Species--
The amino acid
sequence of PP2Ac is highly conserved between species, and budding
yeast contains an endogenous phosphatase activity with biochemical
characteristics remarkably similar to those of mammalian PP2A (33). We
have shown by genetic and biochemical criteria that HsPP2Ac
functionally replaces the endogenous PP2Ac of S. cerevisiae
demonstrating that the evolutionary conservation of PP2Ac structure and
enzyme activity reflects a conservation of function in vivo.
In accordance with this, HsPP2Ac bound the endogenous yeast regulatory
PR65/A subunit consistent with the observation that the most highly
conserved residues in PR65/A localize to a continuous ridge extending
along one face of the molecule. This ridge presents an exposed
hydrophobic surface predicted to contact the PP2A catalytic and other
subunits in the holoenzyme complex (24). Indeed, a mammalian regulatory
B'
subunit of PP2A functionally replaces its homologue (Rts1p) in
S. cerevisiae (38) indicating that the conservation of PP2A
function extends to the holoenzyme.
Inhibitory Mechanism of HsPP2Ac Interfering Mutant
Proteins--
Yeast cells in our screen for PP2Ac
dominant-negative alleles were kept alive by wild type
PP2Ac
expressed at low level from the constitutive
PGK1 promoter, and to inhibit cell growth, dominant-negative
alleles were inducibly expressed from the GAL1 promoter to a
level approximately 10-fold higher (not shown). Thus the
dominant-negative effect of PP2Ac
mutant alleles requires their expression to a higher level than wild type PP2Ac
,
and indeed, PP2Ac
mutant alleles expressed from the
PGK1 promoter did not inhibit cell growth (data not shown).
Moreover, during competition experiments involving simultaneous
overexpression of a PP2Ac
wild type and dominant-negative
allele, the growth inhibition caused by missense alleles was generally
reversed by increased expression of wild type PP2Ac
,
although inhibition caused by nonsense alleles was not. This suggests
that HsPP2Ac proteins containing substitutions compete with wild type
HsPP2Ac in vivo by titrating PP2A regulatory subunits and/or
substrates, whereas truncated forms of HsPP2Ac (and PP2Ac-T258P) may
sequester PP2A subunits and/or substrates irreversibly. Consistent with this we found that, like wild type HsPP2Ac, the PP2Ac-L199P mutant protein bound the endogenous yeast PR65/A subunit suggesting that it
causes an interfering effect by titrating PR65/A into a non-functional complex. Because the core dimer serves as an essential scaffold for the
recruitment of B-type regulatory subunits, PP2Ac-L199P may effectively
titrate other subunits, interfering with targeting and/or substrate
specificity of the wild type enzyme. We found that PP2Ac-L199P is
catalytically impaired and that an active site mutant, PP2Ac-H118N,
causes a similar interfering effect. Only these two mutant proteins
were tested for catalytic activity in vitro, but we have
found that none of the PP2Ac
dominant-negative alleles
supports yeast cell growth when expressed from the PGK1 promoter (not shown) indicating that each may encode a catalytically impaired, yet largely folded protein. Consistent with this, the model
of PP2Ac structure predicts that the interfering forms of HsPP2Ac
either lack or disrupt key metal- or substrate-binding residues
implicated in catalytic function rather than subunit interaction, and
suggests further that even the truncated mutant forms retain a properly
folded portion of the molecule capable of binding regulatory subunits.
In this respect it may be significant that N-terminal sequences of both
PP1 and PPV are implicated in recognizing regulatory subunits (25).
Furthermore, the interfering effect of our HsPP2Ac mutant proteins is
similar to that caused by a mutant form of fission yeast PP2Ac,
containing a substitution equivalent to R239Q in HsPP2Ac, that inhibits
cell growth in a dosage-dependent fashion (39). An
equivalent substitution in the fission yeast PP1c causes aggregation of
the mutant protein and interferes with wild type PP1c function by an
unknown mechanism. This raises the possibility that HsPP2Ac-interfering
proteins may be imperfectly folded and confer their inhibitory effect
by forming aggregates that may trap other PP2A subunits. However, active site mutant forms of protein tyrosine phosphatases can cause an
interfering effect via substrate trapping, protecting substrates from
dephosphorylation by a wild type enzyme (40) suggesting that the
catalytically impaired PP2Ac-L199P and PP2Ac-H118N proteins, and other
interfering HsPP2Ac forms, may exert their effects by causing a similar
protection of PP2Ac substrates. In this study we also generated a
PP2Ac
67 allele in vitro encoding the
N-terminal 67 amino acids of HsPP2Ac and which is similar to a mutant
allele PP2Ac2202 that dominantly enhances
signaling from activated Ras during Drosophila eye
development (41). In our yeast system PP2Ac
67 did not
cause a dominant-negative effect supporting the conclusion that the
phenotype conferred by PP2Ac2202 in heterozygous
insect cells is caused by a reduction in PP2Ac dosage and
not by an intrinsic property of a truncated gene product.
The C-terminal Leucine Is Dispensable for Essential PP2Ac
Function--
The invariant C-terminal leucine residue of PP2Ac is
methylated by a novel transferase enzyme (22) that modulates PP2A
activity and targeting (21, 42). Nevertheless, Leu-309 is dispensable for HsPP2Ac function because a mutant protein lacking this residue supported yeast cell growth in the absence of ScPP2Ac. Because methylation of PP2Ac increases catalytic activity (21), the de-methylated Leu-309 residue may perform an inhibitory role that optimizes PP2A function but is not essential under our growth conditions. Remarkably, removal of Leu-309 from HsPP2Ac was less inhibitory than the abnormal presence of alanine at this position. The
reason for this is unclear but may indicate that the apparent inhibitory role of the PP2Ac C-terminal residue is less easily relieved
when alanine replaces the highly conserved leucine.
Interfering Mutant Forms of Human PP2Ac Generated in
Yeast--
Yeast cells functionally expressing HsPP2Ac provide a
convenient system to identify inhibitory forms, facilitating both the generation of a library of PP2Ac
mutant alleles and the
rapid screening for alleles that inhibit PP2Ac function in
vivo. We generated PP2Ac
dominant-negative alleles
in yeast cells lacking endogenous ScPP2Ac, but when the same alleles
were tested in wild type yeast, they again inhibited cell growth,
indicating an interference with ScPP2Ac. Thus, a screen for growth
inhibitory forms of HsPP2Ac might have been performed in wild type
cells without prior manipulation of the yeast genome, although the
inhibitory effect of the PP2Ac
mutant alleles was more
dramatic when endogenous ScPP2Ac was functionally impaired. Perhaps
ScPP2Ac interacts more efficiently than HsPP2Ac with endogenous yeast
proteins, and unless mutationally impaired, it is less easily
outcompeted by interfering forms of HsPP2Ac. Consistent with this,
HsPP2Ac supported a lower rate of yeast cell growth than ScPP2Ac (Fig.
1B and not shown). Nevertheless, our results suggest that
yeast might be employed to generate interfering forms of other
mammalian proteins, provided there is cross-species conservation of
protein function and especially if a strain containing a non-lethal
mutation in the yeast orthologue is available. Here, this approach has
identified residues important for HsPP2Ac function and catalytic
activity. Moreover, the results of our study provide the first
dominant-negative mutant forms of human PP2Ac, reagents which may be
used to explore the role and regulation of PP2A in a variety of cell
processes and cell types and that will therefore open up new avenues of investigation.
 |
ACKNOWLEDGEMENTS |
We thank Mike Stark (Dundee University) for
strains and plasmids; David Barford (Oxford University) for the
coordinates of the PP1
1 structure; Mike Hall
(Biozentrum, Basel) and P. Mathijs Voorhoeve (NCI, Amsterdam,
Netherlands) for plasmids; Herbert Angliker for DNA sequence analysis;
and Mirjana Andjelkovic, Thomas Millward, and Linda Ireland for
comments on the work.
 |
FOOTNOTES |
*
This work was supported by a Human Frontiers program grant
(to B. A. H.) and a European Union Structural Biology program grant (to B. A. H.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Friedrich Miescher
Institute, Maulbeerstrasse 66, CH-4058, Basel, Switzerland. Tel.
41-61-697-4872; Fax: 41-61-697-3976; E-mail: hemmings@FMI.CH.
2
T. Myles and B. A. Hemmings, manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
PP2A, protein
phosphatase 2A;
PP1, protein phosphatase 1;
PP2Ac, PP2A catalytic
subunit;
5-FOA, 5-fluoroorotic acid;
HsPP2Ac, human PP2Ac;
ScPP2Ac, yeast PP2Ac;
HA, hemagglutinin epitope;
PCR, polymerase chain reaction;
PAS, protein A-Sepharose;
TBS, Tris-buffered saline;
ts, temperature-sensitive;
kb, kilobase pair;
PAGE, polyacrylamide gel
electrophoresis;
ORF, open reading frame.
 |
REFERENCES |
| 1.
|
Cohen, P.
(1989)
Annu. Rev. Biochem.
58,
453-508[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Barton, G. J.,
Cohen, P. T. W.,
and Barford, D.
(1994)
Eur. J. Biochem.
220,
225-237[Medline]
[Order article via Infotrieve]
|
| 3.
|
Barford, D.,
Das, A. K.,
and Egloff, M. P.
(1998)
Annu. Rev. Biophys. Biomol. Struct.
27,
133-164[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Wera, S.,
and Hemmings, B. A.
(1995)
Biochem. J.
311,
17-29
|
| 5.
|
Evans, D. R. H.,
and Hemmings, B. A.
(1998)
Nature
394,
23-24[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Millward, T. A.,
Zolnierwicz, S.,
and Hemmings, B. A.
(1999)
Trends Biochem. Sci.
24,
186-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Mayer, R. E.,
Hendrix, P.,
Cron, P.,
Matthies, R.,
Stone, S. R.,
Goris, J.,
Merlevede, W.,
Hofsteenge, J.,
and Hemmings, B. A.
(1991)
Biochemistry
30,
3589-3597[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Hendrix, P.,
Mayer-Jaekel, R. E.,
Cron, P.,
Goris, J.,
Hofsteenge, J.,
Merlevede,
and Hemmings, B. A.
(1993)
J. Biol. Chem.
268,
15267-15276[Abstract/Free Full Text]
|
| 9.
|
Hendrix, P.,
Turowski, P.,
Mayer-Jaekel, R. E.,
Goris, J.,
Hofsteenge, J.,
Merlevede, W.,
and Hemmings, B. A.
(1993)
J. Biol. Chem.
268,
7330-7337[Abstract/Free Full Text]
|
| 10.
|
McCright, B.,
and Virshup, D. M.
(1995)
J. Biol. Chem.
270,
26123-26128[Abstract/Free Full Text]
|
| 11.
|
Csortos, C.,
Zolnierowicz, S.,
Bako, E.,
Durbin, S. D.,
and DePaoli-Roach, A. A.
(1996)
J. Biol. Chem
271,
2578-2588[Abstract/Free Full Text]
|
| 12.
|
Mayer-Jaekel, R. E.,
Ohkura, H.,
Ferrigno, P.,
Andjelkovic, N.,
Shiomi, K.,
Uemura, T.,
Glover, D. M.,
and Hemmings, B. A.
(1994)
J. Cell Sci.
107,
2609-2616[Abstract]
|
| 13.
|
McCright, B.,
Rivers, A. M.,
Audlin, S.,
and Virshup, D. M.
(1996)
J. Biol. Chem.
271,
22081-22089[Abstract/Free Full Text]
|
| 14.
|
Hubbard, M. J.,
and Cohen, P.
(1993)
Trends Biochem. Sci.
18,
172-177[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Sneddon, A. A.,
Cohen, P. T. W.,
and Stark, M. J. R.
(1990)
EMBO J.
9,
4339-4346[Medline]
[Order article via Infotrieve]
|
| 16.
|
Ronne, H.,
Carlberg, M.,
Hu, G-Z.,
and Nehlin, J. O.
(1991)
Mol. Cell. Biol.
11,
4876-4884[Abstract/Free Full Text]
|
| 17.
|
van Zyl, W,
Huang, W.,
Sneddon, A. A.,
Stark, M.,
Camier, S.,
Werner, M.,
Marck, C.,
Sentenac, A.,
and Broach, J. R.
(1992)
Mol. Cell. Biol.
12,
4946-4959[Abstract/Free Full Text]
|
| 18.
|
Healy, A. M.,
Zolnierowicz, S.,
Stapleton, A. E.,
Goebl, M.,
DePaoli-Roach, A. A.,
and Pringle, J. R.
(1991)
Mol. Cell. Biol.
11,
5767-5780[Abstract/Free Full Text]
|
| 19.
|
Evangelista, C. C.,
Rodriguez-Torres, A. M.,
Limbach, M. P.,
and Zitomer, R. S.
(1996)
Genetics
142,
1083-1093[Abstract]
|
| 20.
|
Di Como, C. J.,
and Arndt, K. T.
(1996)
Genes Dev.
10,
1904-1916[Abstract/Free Full Text]
|
| 21.
|
Favre, B.,
Zolnierowicz, S.,
Turowski, P.,
and Hemmings, B. A.
(1994)
J. Biol. Chem.
269,
16311-16317[Abstract/Free Full Text]
|
| 22.
|
Xie, H.,
and Clarke, S.
(1994)
J. Biol. Chem.
269,
1981-1984[Abstract/Free Full Text]
|
| 23.
|
Xie, H.,
and Clarke, S.
(1994)
Biochem. Biophys. Res. Commun.
203,
1710-1715[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Groves, M. R.,
Hanlon, N.,
Turowski, P.,
Hemmings, B. A.,
and Barford, D.
(1999)
Cell
96,
99-110[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Egloff, M.-P.,
Cohen, P. T. W.,
Reinemer, P.,
and Barford, D.
(1995)
J. Mol. Biol.
254,
942-959[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Goldberg, J.,
Huang, H. B.,
Kwon, Y. G.,
Greengard, P.,
Nairn, A. C.,
and Kuriyan, J.
(1995)
Nature
376,
745-753[CrossRef][Medline]
[Order article via Infotrieve]
|
| 27.
|
Kaiser, C.,
Michaelis, S.,
and Mitchell, A.
(1994)
Methods in Yeast Genetics
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 28.
|
Brunelli, J. P.,
and Pall, M. L.
(1993)
Yeast
9,
1299-1308[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Stotz, A.,
and Linder, P.
(1990)
Gene (Amst.)
95,
91-98[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Evans, D. R. H.,
and Stark, M. J. R.
(1997)
Genetics
145,
227-241[Abstract]
|
| 31.
|
Khew-Goodall, Y.,
Mayer, R. E.,
Maurer, F.,
Stone, S. R.,
and Hemmings, B. A.
(1991)
Biochemistry
30,
89-97[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Voorhoeve, P. M.,
Hijmans, E. M.,
and Bernards, R.
(1999)
Oncogene
18,
515-524[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Cohen, P.,
Schelling, D. L.,
and Stark, M. J. R.
(1989)
FEBS Lett.
250,
601-606[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34. |